This analysis was conducted to evaluate the independent relationship between survival and response to chemotherapy in advanced colorectal cancer. In order to correct for the guarantee time effect, patients dying before the response evaluation were excKlded from the analyses. A (Moertel, 1975 
5-Fluorouracil as a single drug was for many decades the standard treatment in advanced colorectal cancer, but response figures seldomly exceeded 20% and there is no evidence that this treatment prolonged survival (Moertel, 1975) . More recently, several trials have investigated the effects of biochemical modulation of 5-FU, particularly with methotrexate or leucovorin (K6hne-W6mpner et al., 1992) . The response rates were generally higher in the combination arms compared with 5-FU alone, and a survival prolongation was also seen in a few of the individual trials. A survival advantage of about 5 months was observed in patients receiving immediate combination chemotherapy as compared with those receiving delayed (Nordic Gastrointestinal Tumor Adjuvant Therapy Group, 1992) or no treatment (Scheithauer et al., 1993) . These results suggest that combination chemotherapy based on biochemical modulation of 5-FU can prolong survival.
It is generally believed that a beneficial effect of chemotherapy is obtained in patients in whom an objective response is recorded. However, several questions can be asked about the intrinsic value of a response. A recent metaanalysis was not able to verify that patients treated with 5-FU and leucovorin experienced a longer survival than those who received 5-FU alone despite higher response rates in the former group (Advanced Colorectal Cancer Metaanalysis Project 1992) . A small but definite survival prolongation did, however, accompany improved response rates in patients receiving 5-FU and methotrexate in a subsequent meta-analysis (Advanced Colorectal Cancer Meta-analysis Project 1994) . Another unresolved matter concerning the true value of a response is whether responses mainly occur in patients with a favourable prognosis, which would explain why responders invariably have a longer survival than nonresponders (Lavin et al., 1980 ). An additional bias that may contribute to the longer survival seen among responders is the guarantee time effect, i.e. that responders are guaranteed a survival as long as the time to the response evahuation (Anderson et al., 1983 
Material and
Patients included in four chemotherapy trials were studied (Gimeius et al., 1986; Nordic Gastrointestinal Tumor Adjuvant Therapy Group, 1989 . The following inclusion criteria were applied in all trials: metastatic or locally recurrent/inextirpable colorectal cancer, age 75 or younger, Karnofsky performance status 50 or higher, serum creatinine <125mmoll-1, serum bilirubin <40mmoll-1 and no signs of pleural effusion or ascites. Inclusion criteria differed in two respects between the trials: patients previously treated with chemotherapy were eligible only in the phase II trial (Glimelius et al., 1986) and patients with nonmeasurable disease only in one of the phase HI trials (Nordic Gastrointtinal Tumor Adjuvant Therapy Group, 1992 ).
The following requirements had to be met for inclusion in the present study: no previous chemotherapy, at least one course of chemotherapy ad and measurable diseas. The first population comprised 324 patients treated with either 5-FU alone or sequential methotrexate/5-FU/ leucovorin (MFL), and the second population 198 patients treated with MFL or sequential 5-FU and leucovorin (ELv) ( Table I ). We have earlier described prognostic factors in these populations (Graf et al., 1991 . Survival time was measured from on-protocol time to death from any cause. At the time of analysis, 22 patients were alive in the first population (median follow-up 18 months, range 10-72) and 15 in the second population (median follow-up 19 months, range 13-31).
The evaluation of objective responses followed the UICC recommendations (Hayward & Rubens, 1977 evaluations (Miller et al., 1981) . The first evaluation was made after 2 months and subsequent evaluations every second month, i.e. all patients assigned a response or SD were guaranteed a survival of 4 months.
Statistical methods
Except for the first life table in the two populations, all calculations were based on individuals alive after 4 months, which means that the 'landmark method' was used to remove the bias caused by the 'guarantee time' effect (Anderson et al., 1983) . The initial analyses involved the first population. Survival curves were constructed with the actuarial method and differences assessed with the log-rank test. The distribution of patients characteristics by response was evaluated with chi-square or t-tests, as appropriate. Patients with a response or SD were considerd together in these analyses.
The response categories were then tested together with 11 other variables in a Cox (1972) proportional hazards model for influence on survival. The variables in this model were capable of prediction of prognosis in a previous study (Graf et al., 1991) . The results are presented as relative hazards (RH) and 95% confidence limits within parentheses (PD = reference). The use of the multivariate methods can be viewed as a generalisation of the landmarkl method adjusting the estimates for differently distributed prognostic factors. Models in which the hazards were allowed to change over time were also employed. Estimates of survival times connected with each response category were obtained from a model based on the extended generalised gamma distribution (Lawless, 1982) . All analyses were then repeated in the second population to determine if the results could be reproduced in an independent group. In this model, a group of laboratory values were also included, giving a total of 17 variables. This set of variables could also define subsets of individuals according to prognosis . A detailed description of the statistical methods is given in an appendix. (Table II) .
In a Cox multivariate model, the response categories CR, PR and SD (PD = reference category) were the most important variables (P<O.0001). In addition, the haemoglobin (B-Hb) level at trial entry (P = 0.001) and disease-free interval (P = 0.006) contained prognostic information (Table III) . Figure 3 ]. After exclusion of 44 patients with PD and survival less than 4 months, median survival for the PD group rose to 7 months, which was still clearly shorter than the other groups [Xy (3) = 73, P <0.001, Figure 4 ]. Except for a slightly higher Karnofsky performance status, the characteristics of the patients did not differ appreciably between the response plus SD group versus the PD group (Table II) .
In a full multivariate analysis with 17 variables, the response categories had again the strongest relationship to survival (Table MV) . Median survival estimates (after 4 months) with all other variables set at their means were 36.2 months (26.6) for CR, 9.8 months (1.4) for PR, 7.8 months (0.9) for SD and 2.8 months (0.3) for PD.
Disussion
This study showed that although the guarantee time accounts for some of the survival advantage connected with a response, responders also lived much longer than non-re- sponders when the analyses were restricted to patients alive after 4 months, i.e. the minimum survival time to qualify as a responder. Furthermore, adjustment of the differences in patient composition between the responders and non-responders did not result in any major decrease in the importance of a response. Patients with a response were thus not a preselected group, at least not based on the variables included in our models. This finding has clinical implications (Graf et al., 1991) . When response category was included in the analysis, only B-Hb and disease-free interval retained significant prognostic information, whereas MFL lost all prognostic value. This result suggests that the beneficial effect of therapy is expressed in the response or stabilisation effect or, in other words, the type of chemotherapy regimen did not matter for those with progressive disease. Response is thus not just another independent predictor of survival but, at least in this study, the main explanatory variable supporting its use as an end point in clinical trials. An opposite conclusion was reached in the meta-analysis of 5-FU and leucovorin vs 5-FU alone, in which no survival advantage was detected in spite of higher response rates in the former group (Advanced Colorectal Cancer Meta-analysis Project 1992). In addition to the possible explanations for this result proposed by the authors, an alternative explanation might be considered in light of the present findings. In most studies, including the present ones, internationally accepted response criteria have been followed (Miller et al., 1981) . The criteria may, however, be more or less strictly applied.
The above-mentioned meta-analysis included studies using minimum response durations of 4 or 8 weeks. This means that in some studies two response evaluations at least 4 weeks apart were not possible. This short interval may act to weaken an association between response and survival. In contrast, the interval between the response evaluations was always 8 weeks in the present study, and the first was not until after 8 weeks. Furthermore, all responses were independently reviewed. It is possible that these strict criteria increased the likelihood of detecting an association between a response and a prolonged survival.
There are two possible explanations for the strong association between a response and survival: the response may cause the survival prolongation or it may just be a marker for one or several factors that were not included in the analysis. This issue is impossible to settle since one cannot account for all possible prognostic markers. However, in an attempt to challenge our results in the first population, we repeated the analyses in an independent group including also a group of laboratory values in the model. Paterson et al. (1985) in patients with metastatic breast cancer. We have previously noted a strong correlation between an objective and a subjective response. when patients with a response or SD were subjectively improved almost to the same extent (Glimelius et al., 1989 Carlsson et al., 1990) . In light of these findings, it seems reasonable to include patients with SD in some form of 'desirable' response category, provided the stabilisation lasts for a minimum of 4 months.
In conclusion, a response to chemotherapy of 4 months' duration in advanced colorectal cancer is associated with a survival advantage also after correction for the guarantee time effect and the distribution of prognostic variables between the response and non-response groups.
Statstical appendx
In order to study the effect on survival of different explanatory variables, the Cox (1972) One such model with great generality is based on the extended generalised gamma (EGG) distribution (Lawless, 1982) . If survival time T is assumed to follow such a distribution, log survival time can be written as: log T=Po+Blxl + ... +Pkxk+ z where a is a scale parameter and z follows a complicated distribution characterised by a shape parameter gamma. One extremely important feature of this model is that it includes several well-known models as special cases and can be used to distinguish between these models. In the special case y = 0, survival time follows a log-normal distribution, while for = 1 survival time is Weibull distributed. Compared with the Cox model, the model based on the EGG distribution is more general in the sense that it allows non-proportional hazards. It is less general as restrictions on the baseline hazards are imposed. The EGG model and some of its important special cases were estimated by the maximum likelihood method. The exact choice of distribution did not greatly change the conclusions regarding the median survival time in the response categories, nor was the importance of the explanatory variables sensitive to the choice of survival distributions. In addition to members of the extended generalised gamma family, the log-logistic distribution was employed.
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